The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer

Carcinogenesis

Volumn 33, Issue 12, 2012, Pages 2326-2333

  Cui, Tiantian ^a   Chen, Yuan ^a   Yang, Linlin ^a   Knösel, Thomas ^a   Huber, Otmar ^a   Pacyna Gengelbach, Manuela ^b   Petersen, Iver ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DESMOCOLLIN; DESMOCOLLIN 3; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; PRIORITY JOURNAL; TRANSIENT TRANSFECTION; TUMOR SUPPRESSOR GENE; WILD TYPE;

CELL LINE, TUMOR; CELL PROLIFERATION; DESMOCOLLINS; DNA METHYLATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84870323300     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs273     Document Type: Article

References (32)

1. Jemal, A. et al. (2011) Global cancer statistics. CA. Cancer J. Clin., 61, 69-90.
2. Spiro, S.G. et al. (2005) One hundred years of lung cancer. Am. J. Respir. Crit. Care Med., 172, 523-529.
3. Wheelock, M.J. et al. (2001) Cadherin junctions in mammary tumors. J. Mammary Gland Biol. Neoplasia, 6, 275-285.
4. Garrod, D.R. et al. (2002) Desmosomal cadherins. Curr. Opin. Cell Biol., 14, 537-545.
5. Chun, M.G. et al. (2010) Genetic deletion of the desmosomal component desmoplakin promotes tumor microinvasion in a mouse model of pancreatic neuroendocrine carcinogenesis. PLoS Genet., 6, .
6. Nei, H. et al. (1996) Expression of component desmosomal proteins in uterine endometrial carcinoma and their relation to cellular differentiation. Cancer, 78, 461-470.
7. Tada, H. et al. (2000) Expression of desmoglein I and plakoglobin in skin carcinomas. J. Cutan. Pathol., 27, 24-29.
8. Biedermann, K. et al. (2005) Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J. Pathol., 207, 199-206.
9. Khan, K. et al. (2006) Desmocollin switching in colorectal cancer. Br. J. Cancer, 95, 1367-1370.
10. Wong, M.P. et al. (2008) Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. Pathology, 40, 611-616.
11. Oshiro, M.M. et al. (2005) Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res., 7, R669-R680.
12. Wang, L. et al. (2007) Altered expression of desmocollin 3, desmoglein 3, and beta-catenin in oral squamous cell carcinoma: correlation with lymph node metastasis and cell proliferation. Virchows Arch., 451, 959-966.
13. Cui, T. et al. (2011) DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer. Br. J. Cancer, 104, 1013-1019.
14. Monica, V. et al. (2009) Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod. Pathol., 22, 709-717.
15. Tsuta, K. et al. (2011) Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J. Thorac. Oncol., 6, 1190-1199.
16. Normanno, N. et al. (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer, 10, 1-21.
17. Chen, Y. et al. (2007) Homeobox gene HOP has a potential tumor suppressive activity in human lung cancer. Int. J. Cancer, 121, 1021-1027.
18. Oshiro, M.M. et al. (2003) Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene, 22, 3624-3634.
19. Lorch, J.H. et al. (2004) Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J. Biol. Chem., 279, 37191-37200.
20. Dusek, R.L. et al. (2011) Desmosomes: new perpetrators in tumour suppression. Nat. Rev. Cancer, 11, 317-323.
21. Dubash, A.D. et al. (2011) Desmosomes. Curr. Biol., 21, R529-R531.
22. Chen, J. et al. (2012) Loss of Desmocollin 3 in skin tumor development and progression. Mol. Carcinog., 51, 535-545.
23. Das, P.M. et al. (2004) DNA methylation and cancer. J. Clin. Oncol., 22, 4632-4642.
24. Klus, G.T. et al. (2001) Down-regulation of the desmosomal cadherin desmocollin 3 in human breast cancer. Int. J. Oncol., 19, 169-174.
25. Schrump, D.S. et al. (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res., 12, 5777-5785.
26. Zhurinsky, J. et al. (2000) Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J. Cell. Sci., 113 (Pt 18), 3127-3139.
27. Winn, R.A. et al. (2002) gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene, 21, 7497-7506.
28. Yin, T. et al. (2004) Regulation of desmosome assembly and adhesion. Semin. Cell Dev. Biol., 15, 665-677.
29. Yang, L. et al. (2012) Desmoplakin acts as a tumour suppressor by inhibition of the Wnt/beta-catenin signalling pathway in human lung cancer. Carcinogenesis.
30. Kolegraff, K. et al. (2011) Loss of desmocollin-2 confers a tumorigenic phenotype to colonic epithelial cells through activation of Akt/β-catenin signaling. Mol. Biol. Cell, 22, 1121-1134.
31. Wan, H. et al. (2007) Increased keratinocyte proliferation initiated through downregulation of desmoplakin by RNA interference. Exp. Cell Res., 313, 2336-2344.
32. Reddy, K.B. et al. (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev., 22, 395-403.